Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Since my previous article, Caribou Biosciences (NASDAQ: CRBU ) has progressed its gene editing research. It's developing allogeneic therapies against hematological cancers and autoimmune diseases. Currently, CRBU has decided to concentrate on CAR-T therapies and discontinued its CAR-NK platform to optimize resources and extend My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in com ...